Eriko Takatori

No ORCID on file · 2 papers in corpus

2026

Clinical Impact of Olaparib Dose Reduction Compared with Bevacizumab and Standard-Dose Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

·doi:10.20944/preprints202603.0787.v1

Objective: Bevacizumab (BEV) and Olaparib (OLA) have demonstrated clinical efficacy as maintenance therapies for first platinum-sensitive recurrent ovarian cancer. However, direct comparisons between these agents independent of homologous …

review 2016

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review

Journal of ovarian research ·doi:10.1186/s13048-016-0255-6

BACKGROUND: The aims of this report were to describe a case of ovarian adenosquamous carcinoma and to systematically review the pertinent literature. METHODS: We describe a case in which a 57-year-old woman had stage IC ovarian cancer histo…